1. Home
  2. CDT vs ATXG Comparison

CDT vs ATXG Comparison

Compare CDT & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • ATXG
  • Stock Information
  • Founded
  • CDT 2019
  • ATXG 2014
  • Country
  • CDT United States
  • ATXG China
  • Employees
  • CDT N/A
  • ATXG N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • ATXG Professional Services
  • Sector
  • CDT Health Care
  • ATXG Consumer Discretionary
  • Exchange
  • CDT Nasdaq
  • ATXG Nasdaq
  • Market Cap
  • CDT 4.6M
  • ATXG 3.8M
  • IPO Year
  • CDT N/A
  • ATXG N/A
  • Fundamental
  • Price
  • CDT $1.18
  • ATXG $0.55
  • Analyst Decision
  • CDT
  • ATXG
  • Analyst Count
  • CDT 0
  • ATXG 0
  • Target Price
  • CDT N/A
  • ATXG N/A
  • AVG Volume (30 Days)
  • CDT 160.1K
  • ATXG 129.6K
  • Earning Date
  • CDT 08-14-2025
  • ATXG 08-14-2025
  • Dividend Yield
  • CDT N/A
  • ATXG N/A
  • EPS Growth
  • CDT N/A
  • ATXG N/A
  • EPS
  • CDT N/A
  • ATXG N/A
  • Revenue
  • CDT N/A
  • ATXG $4,310,835.00
  • Revenue This Year
  • CDT N/A
  • ATXG N/A
  • Revenue Next Year
  • CDT N/A
  • ATXG N/A
  • P/E Ratio
  • CDT N/A
  • ATXG N/A
  • Revenue Growth
  • CDT N/A
  • ATXG N/A
  • 52 Week Low
  • CDT $1.16
  • ATXG $0.36
  • 52 Week High
  • CDT $274.80
  • ATXG $1.86
  • Technical
  • Relative Strength Index (RSI)
  • CDT 24.09
  • ATXG 53.61
  • Support Level
  • CDT $1.47
  • ATXG $0.44
  • Resistance Level
  • CDT $1.36
  • ATXG $0.58
  • Average True Range (ATR)
  • CDT 0.11
  • ATXG 0.05
  • MACD
  • CDT -0.01
  • ATXG 0.01
  • Stochastic Oscillator
  • CDT 3.51
  • ATXG 64.71

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Share on Social Networks: